

- **Abrahams NA, G T MacLennan¹, Khoury¹ J D** Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray *Int Urol Nephrol*. 2005;37(3):439-45.
- **Adeyema BF, Kolude BM, Akang E et al.** The utility of AgNORs in categorization and prognosis of salivary glands tumors. *J of Surg Oncolog* 67 pp 17-23, 2006.
- **Adley B.P, Smith R. Nayar and Yang X.J.** Birt–Hogg–Dubé syndrome: clinicopathologic findings and genetic alterations, *Arch Pathol Lab Med* **130** 1865–1870. (2006),
- **Alam NA, Bevan S, Churchman M.et al** : Localizasion of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-43. *Am J Hum Genet* 68: 1264-1269.2001
- **Allory Y, Matsuoka Y, Bazille C,** The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. *Clin Cancer Res*. 2005 Feb 1;11(3):1190-7
- **Alos L, Lujan B, Castillo M, Nadal A** Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands. *Am J Surg Pathol*. 2005 Jun;29(6):806-13.
- **Alper CH:** the kidney. In Robbins and Cotran Pathologic basis of Diserases. 7th ed. WB. Saunders Company p1015:1019, 2005.
- **American Cancer Society.:** Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society, 2006.

- **Amin MB, Tamboli P, Javidan T et al.** Prognostic impact of histologic subtypes of adult renal epithelial neoplasm. *Am J Sur Pathol*, 26:281-291, 2002.
- **Argani M, Lae E, Ballad et al,** Translocation carcinoma of the kidney after chemotherapy in childhood. *J Clin Oncol* 24.p:1529-1534, 2006.
- **Argani P and Ladanyi M.** Renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions. WHO classification of tumors, pathology and genetics. Tumors of the urinary system. P10-43, 2004.
- **Argina P , Antonescu Cr, Ille3i P et al.** primary renal neoplasm with the ASPL-TFE 3 gene fusion. *Am J Pathol* 159 pp, 179-192, 2001.
- **Argina P and Ladanyi M.** the evolving story of renal translocation carcinoma. *Am J Clin Pathol* 126. pp1-4, 2006
- **Aron M,., Nguyen M, Robert J. et al .** Impact of Gender in Renal Cell Carcinoma: An Analysis of the SEER Database. *European Urology*, In Press, Corrected Proof, Available online 17 December 2007
- **Ashley JB.** Tumors of the kidney. In Evans' histological Appearance of tumors. Churchill Livingstone. P 899-920.1990. Assessment of stage T1 for RCC. *Int Braz J Urol*;29:106-12
- **Atuk NO ,Stolle C, Owen JA et al,** pheochromocytomain VHL disease ,*J Clin Endocrinol Metab* 83;117-120 . (1998)
- **Baek SK, Woo JS, Kwon SY et al.** Prognostic significance of the MUC-1 expression in thyroid papillary carcinoma. *Laryngoscope* 117 pp 911-917, 2007.

- **Bahnson R.** Prognosis of Renal Cell Carcinoma. *The Journal of Urology*, Volume 177, Issue 4, April 2007, Page 1224.
- **Barker KT, Bevan S, Wang R, et al.** Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. *Br J Cancer* 2002;**87**:446–8
- **Belldegrun AS** .Prognostic factors and patient selection . EUS vol 6, pp477-483, 2007.
- **Beltran AL , Scarpelli M, Montironi. R** 2004 WHO Classification of the Renal Tumors of the Adults. *European Urology*, Volume 49, Issue 5, May 2006, Pages 798-805.
- **Beroud, C. et al. ((2000)** Software and database for the analysis of mutations in the VHL gene. *Nucleic Acids Res* 26, 256-258.
- **Blankenship C, Naglich J, Whaley J, et al.** Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. *Oncogene*;18:1529-35. 1999.
- **Bodmer D, W. Hurk V, Groningen J, Eleveld M J, et al** Understanding familial and non-familial renal cell cancer. *Hum. Mol. Genet.*, October 1, 2002; 11(20): 2489 - 2498.
- **Bonsib SM, Gibson D, Mhoon M et al:** Renal sinus involvement in RCC. *Am J Surg Pathol* 2000, 24:451-458
- **Bottaro DP, Rubin JS, Faletto DL, Chan AM,.** Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*, 251: 802-804, 1991.
- **Brayman M, Thathiah A and Daniel D.** Carson: MUC1: A multifunctional cell surface component of reproductive tissue epithelia. *Reproductive Biology and Endocrinology* 2004 Vol2

- **Bretheau D, Lechevallier E, Marc de Formont et al** Prognostic value of nuclear grade of renal cell carcinoma,: Cancer ,1995, 76,2543-2549).
- **Brossart P., Heinrich KS, Stuhler G Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies** Blood, Vol. 93 No. 12 (June 15), 1999: pp. 4309-4317.
- **Brugarolas J.** Renal-Cell Carcinoma — Molecular Pathways and Therapies. The new England Journal of medicine Volume 356:185-187.2007
- **Bui MH, Visapaa H, Seligson D et al.** Prognostic value of carbonic anhydrase IX as predictors of survival for renal cell carcinoma. J Urol 171, pp 2461-6, 2004.
- **Bukowski MR and Novick AC.** The epidemiology of renal cell carcinoma Current Clinical Oncology p3-13, 2000
- **Cancer Genetics Web** www.cancer-genetics.org
- **Ceccarelli C, Trerè D., Santini D., ,et al .**AgNORs in breast tumours Micron, Volume 31, Issue 2, , 143-149, April 2000
- **Chao D, Zisman A ,Puntuck, et al.** Collecting duct carcinoma. J Urol 167P 71-74 ,2002.
- **Chauhan SC, Sing AP, Ruiz F.** Abberent expression of MUC in ovarian carcinoma. Mod Pathol,19 pp, 1386-1394, 2007.
- **Chen F, Kishida T, Yao M, et al .** Germline mutation in the VHL tumour suppressor gene, Hum.Mutat., 5;66-77 1995.
- **Cheville JC, Lohse CM, Zinche H et al.** Sarcomatoid renal cell carcinoma: Am J Sur Pahol 28(4): 435-41, 2004.

- **Roland CL, Harker AH, Sarra MG et al. ICAM expression determines malignant potential of cancer. Surg, 41, pp, 705-707, 2007**
- **Clark J, Lu YJ, Sidhar SK, Parker c et al 1997:** Fusion of splicing factor genes PSF and NonO to the TFE3 gene in PCRCC;Oncogene 15;2233-2239
- **Clifford SC, Astuti D, Hooper L, et al.** The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. *Oncogene* 2001;**20**:5067–74.
- **Cloosen, S., Arnold, J., Thio, M., Bos, G. M.J., (2007).** Expression of Tumor-Associated Differentiation Antigens, MUC1 Glycoforms and CEA, in Human Thymic Epithelial Cells: Implications for Self-Tolerance and Tumor Therapy. *Cancer Res.* 67: 3919-3926
- **Cohen H. T. and. McGovern F. J** Renal-CellCarcinoma N. Engl. J. Med., 353(23): 2477 - 2490 December 8, 2005.
- **Contractor H, Zariwala M, Bugert P et al:** Mutation of the p53 tumor suppressor gene occurs in prefentially in the chromophobe type of renal cell tumors J Pathol 181: 136-139. 1997
- **Contractor H, Zariwala M, Bugert P et al:** Mutation of the p53 tumor suppressor gene occurs in prefentially in the chromophobe type of renal cell tumors J Pathol 181: 136-139. 1997
- **Corti B, Zucchini N, Fabbrizio B** Pathology and Molecular Pathogenesis of Renal Cell Carcinoma. *European Urology Supplements*, Volume 5, Issue 8, June 2006, Pages 573-579
- **Covello kl,. Simon MC, and. Keith B.** Targeted Replacement of Hypoxia-Inducible Factor-1{alpha} by a Hypoxia-Inducible

Factor-2{alpha} Knock-in Allele Promotes Tumor Growth Cancer Res; 65(6): 2277 - 2286., March 15, 2005

- **Croce M V, Isla-Larrain MT, Rua C E.** Patterns of MUC1 Tissue Expression Defined by an Anti-MUC1 Cytoplasmic Tail Monoclonal Antibody in Breast Cancer Journal of Histochemistry and Cytochemistry, Vol. 51, 781-788, June ,2003
- **Crocker J and Egan MJ.** Correlation between NOR sizes and numbers in non-Hodgkins lymphomas. J Pathol 1988; 156:233-9.
- **Crocker J.** Nucleolar organizer regions. Curr Top Pathol 1990;82:91-149
- **Crotty TB, Farrow GM, Lieber MM et al:** Chromophobe RCC.J Urol 154:964-967). ,1995.
- **Dall'Oglio MF, Antunes AA, Sarkis AS** Microvascular tumor invasion in renal cell carcinoma: The most important prognostic factor:, , Division of Urology, University of Sao Paulo Medical School, Sao Paulo, Brazil. Urologic Oncology: Seminars and Original Investigations, Volume 26, Issue 1, January-February 2008, Pages 98-99.
- **Datta MW, , Ulbright TM, Young RH et al:** RCC metastatic to the testis and its exa. Int J Surg Pathol, , 9: 49-56. 2001
- **Del Vecchio MT, Lazzi S, Bruni A et al 1998:** DNA ploidy pattern in PRCC: Correlation with clinicopathological parameters . Pathol Rec Pract 194: 325-333
- **Delahunt B, , Bethwaite PB, , Thornton A, et al.** Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome.Cancer Volume 75, Issue 11 , Pages 2714 – 2719, 2006.
- **Delanhut B , Kittelson JM, McCredie MR et al.** Prognostic importance of tumor size for localized clear cell renal cell carcinoma , cancer, 94,pp: 658-664, 2002.

- **Delanhut B and Eble JN** .Papillary renal cell carcinoma .Mod Pathol,10:537-544,1997
- **Delanhut B and Eble JN**. Papillary renal cell carcinoma In WHO classification of tumors, Pathology and genetics, Tumors of urinary system and male genital organs P 10-43, 2004.
- **Derenzini M, Siri V, Trere D**. The quality of nucleolar protein nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest 73 pp:497-502, 1995.
- **Derenzini M**. TheAgNORs. Micron. 2000 Apr;31(2):117-20
- **Drucker BJ Renal cell carcinoma: current status and future prospects**. Cancer Treat Rev.;31(7):536-45. 2005
- **Dry SM and Renshaw AA, :** Extensive calcium oxalate crystals deposition in PRCC. Arch Pathol Lab Med 122: 260-261 1998.
- **Dulaimi E, Ibanez de Caceres,, Uzzo ^{GR}** · Promoter Hypermethylation Profile of Kidney Cancer .Clinical Cancer Research Vol. 10, 3972-3979, June 15, 2004.
- **Dulaimi E, Inmaculada Ibanez de Caceres¹, Robert G. Uzzo**
- **Durham JR, Keohane M, Amin MB:** Chromophobe RCC: .Adv Anat Pathol 3:336-342. 1996.
- **Ebel JN**. Multilocular cystic renal cell carcinoma. In WHO classification of tumors, pathology and genetics.P10-43,2004.
- **Eble JN ,Bonsib SM,:** Extensively cystic renal neoplasm. Semin Diagn Pathol 15: 2-20 1998.
- **Eble JN and Young RH**. Tumors of the urinary tract .In Diagnostic Histopathology of tumors .2nd ed. Churchill Livingstone, 475-512, 2000.

- **Eble Jn, Togasdh K, Pisani P.** Renal cell carcinoma. In WHO classification of tumors, pathology and genetics. Tumors of the urinary system. P10-43, 2004.
- **El Bolkiany MN, El- hattab O and Nouh A .**The SEER staging of cancer .The Ntional cancer institute, Cairo University, 19-20, 1997.
- **El Bolkiany MN, Nouh A and El- Blokainy TN.** Cancer of urinary tract. In Topographic Pathology of cancer 3rd ed. NCI, Cairo University. P53-55, 2005.
- **El-Kott AF, Ismaeil MF, El-Moneim MM, et al .** Int Urol Nephrol.;37(3):439-45. 2005
- **Elmore JM, Kadesky KT, Koeneman KS.** Reassesment of the 1997 TNM classification system for renal cell carcinoma. Cancer 11, pp 2329-34. 2003.
- **Erlandson RA, Shek TW, Reuter VE et al :** Diagnostic Significance of mitochondria in four types of renal epithelial tumors: an altra structure study of 60 tumours. Ultrastruct Pathol 21: 409-417 1997.
- **Ficarra V , Galfano A, Mancini M, et al .** TNM staging system for renal-cell carcinoma: current status and future perspectives. The Lancet Oncology, Volume 8, Issue 6, , Pages 554-558 June 2007
- **Ficarra V, G. Martignoni and C. Lohse et al.,** External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) Score to predict cancer specific survival using a European series of conventional renal cell carcinoma, J Urol **175**), pp. 1235–1239. 2006

- **Ficarra V, Galfano A, Verhoest G.** Prognostic Factors and Staging Systems for Renal Cell Carcinoma European Urology Supplements, Volume 6, Issue 10, May 2007, Pages 623-629.
- **Flaherty KT, Fuchs CS, Colditz GA, et al.** A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control;16(9):1099-106. 2005 Nov
- **François C, Moreno C, Teitelbaum J et al.** Improving accuracy in the grading of renal cell carcinoma by combining the quantitative description of chromatin pattern with the quantitative determination of cell kinetic parameters. Communications in Clinical Cytometry Volume 42, Issue 1, Pages 18 – 26, 2000
- **Fryzek JP, Poulsen AH, Johnsen SP.** A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005 Apr 11;92(7):1302-6..
- **Fuhrman S.A., Lasky L.C and. Limas C,** Prognostic significance of morphologic parameters in renal cell carcinoma, Am J Surg Pathol 6), pp. 655–663.1982
- **Fujita K, Denda K, Yamamoto M et al.** Expression of mucins inversely correlated with renal cell carcinoma patients. Br J Cancer, 1999, 80 pp 301-308
- **Furge KA, Lucas KA, Takahashi M, et al.** Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004;64:4117–21.
- **Furge KA, Zhang YW, Vande Woude GF.** Promoter Hypermethylation Profile of Kidney Cancer Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 19: 5582-5589, 2000.

- **Gad S., Lefevre S.H., Khoo S.K, et al** , Mutations in *BHD* and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma, Br. J. Cancer (2006).
- **Gallou C, Chauveau D, Richard S**, Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat. 2004 Nov;24(5):435-6.
- **Garcia JA and Rini BI**. Recent Progress in the Management of Advanced Renal Cell Carcinoma. CA Cancer J Clin 2007; 57:112-125.
- **Gendler SJ and Spicer AP**: Epithelial mucin genes. Annu Rev Physiol 1995, 57:607-634
- **Generra JR, Tory K, Weng Y et al**. Mutations of VHL tumor suppressor gene in renal carcinoma. Nat. Genet, 7, pp:85-90, 1994
- **George DJ and Kaelin WG** , The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med;349:419-21. 2003.
- **Ghazizadeh M, Sasaki Y, Araki T et al**. Prognostic value of proliferative activity in ovarian carcinoma .Am J Clin Pathol, 107, pp:451-458, 1997.
- **Giacomo N, Guido M , Walter A et al**, Grading systems in Renal cell carcinoma. Urology, 177,430-436,2007.
- **Gimenez Bachs JM, Salinas Sanchez AS, Sanchez Sanchez F et al**. Determination of VHL gene mutations in sporadic renal carcinoma. Eur Urol 49, pp 1051-1057, 2006
- **Glickman JN, Blount PL, Sanchez CA et al**. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol, 37, pp 1304-1315, 2005.

- **Gnarra JR, Tory K, Weng Y, et al .** Mutation of the VHL tumour suppressor gene in RCC , Nat. Genet., 7; 85-90 1994.
- **Gottwald L, Danilewicz M, Suzin J, et al.** Pol J Pathol. 2003;54(4):239-42. Links
- **Greenberg R, Barnea Y, Kaplan O.** Detection of cancer cells in the axillary drainage after porations for breast cancer. The Breast , 13, pp 49-55, 2004.
- **Grignon DJ Eble JN, Bonsib SM.** Clear cell renal cell carcinoma. In WHO classification of tumors, pathology and genetics. Tumors of the urinary system. P10-43, 2004.
- **Grosso Joseph F and Lynn M.** MUC1/sec-Expressing Tumors Are Rejected In Vivo by a T Cell-Dependent Mechanism and Secrete High Levels of CCL2 The Journal of Immunology, 2004, 173: 1721-1730.
- **Grotto H Z, Metze K, Lorand-Metze I et al.** Pattern of nucleolar organizer regions in human leukemic cells. Anal Cell Pathol. 1993 Jul ;5 (4):203-12
- **Groulx I and Lee S** Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 2002;22:5319-36.
- **Gunaratnam L, Morley M , Franovic A et al.** Hypoxia Inducible Factor Activates the Transforming Growth Factor- α /Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL^{-/-} Renal Cell Carcinoma Cells J. Biol. Chem., Vol. 278, Issue 45, 44966-44974, November 7, 2003

- **Gunawan B, Huber W, Holtrup M,** Prognostic Impacts of Cytogenetic Findings in Clear Cell Renal Cell Carcinoma *Cancer Research* 61, 7731-7738, November 1, 2001
- **Gunawan B, von Heydebreck A, Fritsch T, et al.** Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. *Cancer Res* 2003;63:6200–5.
- **Haddad FS, Shan IA, Manne RK et al,:** Renal cell carcinoma insulted in the renal capsule with calcification and ossification urol Int 51: 97-101. **1993**
- **Halat S K and. MacLennan G T** Multilocular Cystic Renal Cell Carcinoma The Journal of Urology, Volume 177, Issue 1, January 2007, Page 343
- **Hamano K, Esumi M, Igarashi H et al:** Biallelic inactivation of the VHL TSG in sporadic RCC J Urol, 167 :713-717 2002
- **Heimann P, , Housni I, Ogur G et al :** Fusion of a novel gene RCC17 to the TFE3 gene in t(X;1&)(p11,2;q25.3) bearing papillary RCC. *Cancer Rec* 61:4130-4135.2001.
- **Heinzer h, Eichelberg C, Heuer R.** Prognostic Factors in Kidney Cancer and New TNM Classification. *European Urology Supplements*, Volume 7, Issue 5, April 2008, Pages 434-435.
- **Heliot L, Kaplan H, Lucas L, et al** Electron Tomography of Metaphase Nucleolar Organizer Regions: Evidence for a Twisted-Loop Organization Vol. 8, Issue 11, 2199-2216, November 1997
- **Herbert L M.,. Grosso¹ J F, Dorsey M.A** Unique Mucin Immunoenhancing Peptide with Antitumor Properties. *Cancer Research* 64, 8077-8084, November 1, 2004.

- **Hergovich A, Lisztwan J, Barry R, et al .** Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.. HGF induced Ras pathway by binding to a multifunctional Nat Cell Biol 2003;5:64-70
- **Herman JG, Latif F, Weng Y, et al** Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:97
- **Hey N A, Meseguer M, Simón CR** · Biol Endocrinol. 2003; 1: 2. Transmembrane and truncated (SEC) isoforms of MUC1 in the human endometrium and Fallopian tube
- **Higuchi T, Orita T, Katsuya K et al:** MUC20 suppress the Hoffman MA, Ohh M, Yang H, Kline JM, Ivan M, Kaelin WG Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-1027.
- **Hock L.M., Lynch J. and. Balaji K.C,** Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data, *J Urol* **167** (2002), pp. 57–60.
- **Hoffman, M.A., Ohh, M., Yang H et al.** VHL gene- protein mutated linked to type 2C VHL disease preserve the ability to downregulate HIF Hum.Mol. Genet.,10;1019-1027. 2001
- **Hollingsworth J.M., Miller D.C, Daignault S.,et al** , Rising incidence of small renal masses: a need to reassess treatment effect, *J Natl Cancer Inst* **98** pp. 1331–1334 (2006),
- **Houwelingen* KP ,van DijkAC, van de Kaa AH, et al** Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell

carcinoma: results from the Netherlands cohort study *BMC Cancer* 2005, 5:57 .

- **Huang L., Chen D., Liu D**, MUC1 oncoprotein blocks glycogen synthase kinase 3 β -mediated phosphorylation and degradation of beta-catenin, *Cancer Res* **65** (22) (2005), pp. 10413–1042.
- **Hutson TE** , DO, PharmD¹ Proc (Bayl Univ Med Cent). ¹From the Division of Oncology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas. 2005 October; 18(4): 337–340
- **Ianchez LE , Lucon M, Nahas W C** Renal Cell Carcinoma in Renal Transplant Patients. *Urology*, Volume 69, Issue 3, March 2007, Pages 462-464
- **Iliopoulos O and Eng C** . Genetic and clinical aspect of familial renal neoplasm. *Semin oncol.* 27,pp 138-149, 2000
- **Iliopoulos O, Ohh M, Kaelin W**. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. *Proc Natl Acad Sci USA* 1998;95:11661-6.
- **Ivan M, Kondo K, Yang H, et al**. HIF targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science* 2001;292:464–8.
- **Ivan. M and Kaelin ,W.G.**2001.The VHL tumor suppressor protein. *Curr.Opin. Genet.Dev.* 11; 27-34.
- **Ivanov S, Liao, S.Y, Ivanova A ,et al** (2001):Expression of hypoxia-inducible cell surface transmembrane carbonic anhydrases in human cancer. *Am. J . Pathol*, 158;905-919.
- **Jemal A, Murray T, Ward E, et al**. Cancer statistics, 2007. *CA Cancer J Clin.* 2007;55:10–30.

- **Jennifer J. Kovacs, G:** Molecular differential pathology of renal cell tumors Histopathology 2,1-8 1993.
- **Jiang F , RichterJ, Schraml P et al .** Chromosomal Imbalances in Papillary Renal Cell Carcinoma (American Journal of Pathology. 1998;153:1467-1473.)
- **Johnson GC, Miller MA, Romas-Vara JA et al,** Comparison of argyrophilic nucleolar organizer regions in distinguishing benign from malignant smooth muscle tumors. J Vet Diagn Invest, 7 pp 127-136, 1995.
- **Jones T.D, Eble J.N. , Wang M.et al.,** Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation, Cancer **104**), pp. 1195–1203 (2005
- **Joo HJ, Oh DK, Kim Ys et al, .** Increased expression of Caveolin and microvessel density correlates with metastases and poor prognosis in renal cell carcinoma. BJU Int 93 pp 291-296, 2004
- **Jorge R. T and Nickerson M L.** Mutations in the *Fumarate Hydratase* Gene Cause Hereditary Leiomyomatosis and Renal Cell Cancer in Families in North America Am J Hum Genet. July 2003; 73(1): 95–106
- **Kaelin WG Jr.** The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-6295S
- **Kaelin WG Jr.** The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s.
- **Takeji Y, Korenaga D, Tsujitani S, et al .** Predictive value of Ki-67 and argyrophilic nucleolar organizer region staining for lymph node metastasis in gastric cancer. Cancer Res 1991;51:3503-6

- **Kaku H, Ito S, Ebara S, Ouchida M** Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma. *Urology*. 2004 Jul;64(1):176-81.
- **Karakiewicz P I, Trinh QD, Alexandre de la Taille**. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. *European Journal of Cancer, Volume 43, Issue 6, April 2007, Pages 1023-1029*.
- **Karakiewicz P.I., Lewinshtein D.J , Chun F.K et al.**, Tumor size improves the accuracy of TNM predictions in patients with renal cancer, *Eur Urol* **50** (2006), pp. 521–529
- **Kashyap MK, Kumar A, Emelianenko N** Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. *Biomarkers*. 2005 Jul-Aug;10(4):258-94.
- **Kato K, Ijiri R, Tanaka Y et al** : Metachronous RCC in a child cured of neuroblastoma. *Med Pediatric Oncol* 33:432-433 1999.
- **Kawata N, Nagane Y, Hirakata H** Significant Relationship of Matrix Metalloproteinase 9 with Nuclear Grade and Prognostic Impact of Tissue Inhibitor of Metalloproteinase 2 for Incidental Clear Cell Renal Cell Carcinoma. *Urology, Volume 69, Issue 6, June 2007, Pages 1049-1053*
- **Khanna AJ , Yadav SK , Dixit VK ,. Et al** AgNOR Count and Subjective AgNOR Pattern Assessment (SAPA) Score in Carcinoma Head of Pancreas Including Periapillary Tumor *JOP. J Pancreas (Online)* 2005; 6(6):575-580
- **Khanna AK, Ansari MA, Kumar M, et al** . Correlation between AgNOR count and subjective AgNOR pattern assessment score in cytology and histology of breast lumps. *Anal Quant Cytol Histol* 2001; 23:388-94.

- **Khoo SK, Kahnoski K,, Sugimura J et al**(2003): Inactivation of BHD in sporadic renal tumors. *Cancer Res.* 62; 4583-4587
- **Khoury JD, Abrahams NA, Levin HS** The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma. : *Ann Diagn Pathol.* 2002 Jun;6(3):154-8.
- **Kida Y, Yamaguchi K, Suzuki H.** Tuberous sclerosis, associated with renal cell carcinoma and angiomyolipoma, in a patient who developed endstage renal failure after nephrectomy. *Clin Exp Nephrol.* 2005 Jun;9(2):179-82.
- **Kim CM .** Expression of Hypoxia Inducible Factor-1 α and 2 α in Genetically Distinct Early Renal Cortical Tumors. *The Journal of Urology, Volume 175, Issue 5, May 2006, Pages 1908-1914*
- **Kim H ,Belldegrun A, Freitas et al,** paraneoplastic and symptoms of renal cell carcinoma. *J Urol* 170.P1742-1746, 2003.
- **Kim WY and Kaelin WG.** The role of VHL gene mutation in human cancer. *J Clin Oncol.* In press 2004.
- **Kiuru M, Lehtonen R, Arol J.** Few *FH* Mutations in Sporadic Counterparts of Tumor Types Observed in Hereditary Leiomyomatosis and Renal Cell Cancer Families¹ *Cancer Research* 62, 4554-4557, August 15, 2002
- **Kiuru M :** Molecular basis of HLRCC, 2002
- **Kiuru M, Launonen V, Hietala M, et al.** Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. *Am J Pathol* 2001;159:825-829

- **Klatte T, Patard J.J, Goel R.H et al.**, Prognostic impact of tumor size on pT2 renal cell Carcinoma: an international multicenter experience, *J Urol* **178**, pp. 35–40 (2007)
- **Klatte T, Patard JJ, Goel RH, Kleid MD**: Prognostic impact of tumor size on pT2 renal cell carcinoma: An international multicenter experience:, , Department of Urology, University of California, Los Angeles, CA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France. *Urologic Oncology: Seminars and Original Investigations*, Volume 26, Issue 1, January-February 2008, Pages 100-101.
- **Kondo K and Kaelin W.G.,Jr.** The VHL suppressor gene *Exp.Cell Res.*264, 117-125. 2001
- **Kondo K, Klco J, Nakamura E, et al .** Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell* 2002;1:237-46.
- **Korenaga Y, Matsuyama H, Hirata H.** Smoking may cause genetic alterations at 5q22.2 approximately q23.1 in clear-cell renal cell carcinoma. [Cancer Genet Cytogenet.](#) 2005 Nov;163(1):7-11
- **Korneyev I A, Mamaev N N, Kozlov V V.** Interphase argyrophilic nucleolar organiser regions and nucleolar counts in transitional cell bladder tumours. *Mol Pathol.* 2000 June; 53(3): 129–132.
- **Kovacs G and Hoene(1988)**: Loss of der 3 in RCC of patients with constitutional t(3;12). *Hum Genet* 78:148-150
- **Kovacs G, Fuzesi L, Emanuel A, Kung HF.** Cytogenetics of papillary renal cell tumors. *Genes Chromosomes Cancer* 1991; 3: 249–255

- **Kovacs G., Akhtar , m., Beckwith, B, J., et al** : The Heidelberg classification of renal cell tumors J. Pathol 183,131-133 1997.
- **Kovacs G:** Molecular differential pathology of renal cell tumors Histopathology 2,1-8 1993.
- **Koyle MA, Htch DA, Furness PD3rd et al** : Long-term urological complication in survivors younger than 15 months of advanced stage abdominal neuroblastoma. J Urol 166;1455-1458.2001
- **Kraus S, Abel PD, Nachtmann FC** .MUC-1 and trefoil factor 1 protein expression in renal cell carcinoma . Hum Pathol 33 ,pp 60-67, 2002
- **Kuehn EW, Walz G, Benzing T.** VHL : a tumor suppressor links microtubules to ciliogenesis and cancer development. Cancer Res. 2007 May 15;67(10):4537-40.
- **Kundson AG.** VHL Gene mutation and renal cell carcinoma, Cancer J. Scientif. AM., 1;1801-1805, 1995.
- **Kundson AG.**..Mutation and cancer: statistical study of retinoplastoma. Proc Natl. Acad. Sci. USA ,68; pp: 820-823, 1971
- **Kyle A., Furge , Kerry A., et al** : Robust classification of RCC: Cancer Res: 64: 4117-4121 2004.
- **LaGrange C A, Subodh M. Lele and Stephen E. Strup** Renal Cell Carcinoma Associated with TFE3 Gene Fusion in an Elderly Woman Urology, Volume 70, Issue 3, September 2007, Pages 590.e11-590.e12
- **Lam J S, Klatte Ts., Kim H L,et al** .Prognostic factors and selection for clinical studies of patients with kidney cancer. Critical

Reviews in Oncology/Hematology, Volume 65, Issue 3, March 2008, Pages 235-262.

- **Lam JS, Shvarts O, Lappert JT et al renal cell carcinoma 2005:** new frontiers in staging, prognosis and molecular therapy. J Urol vol 173 pp 1853-1862, 2005
- **Langer C, Ratschek M, Rehak P et al,.** Expression of MUC-I and E-cadherin in renal cell carcinoma.Mod Pathol, 17 pp 180-188, 2004
- **Latif F, Tory K, Gnarr J et al** 1993: Identification of VHL disease tumor suppressor gene.Sience 260;1317-1320.
- **Launonen V, Vierimaa O, Kiuru M , et al :** Inherited suscepability to uterine leiomyomas and renal cell carcinoma. Proc Natl acad Sci USA 98: 3387-3392 2001.
- **Lee SJ, Baptiste Lattouf J, Xanthopoulos J et al,** VHL tumor suppressor gene loss in renal cell carcinoma. Eur Urol, in press, 2008
- **Lehtonen H J, Blanco I., Piulats J M.** Conventional renal cancer in a patient with fumarate hydratase mutation. *Human Pathology, Volume 38, Issue 5, May 2007, Pages 793-796*
- **Lehtonen Jr, Kiuru M, Vanharanta S et al:** Biallelic inactivation of FH occurs in non syndromic uterine leiomyomas but is rare in other tumors .Am J Pathol 2003
- **Leroy X, Copin MC, Devisme L et al.** Expression of human mucin genes in normal kidney and renal cell carcinoma.Histoathlogy 0p, 450-457, 2002.
- **Leroy X, Zini L, Leteutre E et al.** Morphological subtyping of papillary renal cell carcinoma : Correlation with prognosis of MUC-1 . Mod Pathol 15 pp, 1126-1130, 2002

- **Levi F, Lucchini F, Negri E et al.** Cancer mortality in Europe, 1995–99, and an overview of trends since 1960. *Int J Cancer* 2004; **110**: 155–169
- **Li Y and Cozzi PJ .** MUC-1 is a promising therapeutic target for prostate cancer therapy, *Curr Cancer Drug Target* , 7,pp 259-271, 2007.
 - **Li Y, Lui D, Chen G et al.** Human DF3/MUC1 carcinoma associated protein functions as oncogene. *Oncogene*, 22 pp 6107-6110, 2003.
 - **Li Z, Na X, Wang D, Schoen SR,** et al Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. *J Biol Chem* 2002;277:4656-62.
 - **Lidgren A, Hedberg Y, Grankvist K** Hypoxia-Inducible Factor 1 α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray. *European Urology, Volume 50, Issue 6, December 2007, Pages 1272-1277*
 - **Lidgren A, Hedberg Y, Grankvist K et al.** The expression of HIF is a favorable prognostic factor in renal cell carcinoma. *Clin Cancer Reserch*. 11 pp 1129-1135, 2005.
 - **Lindblad P .**Epidemiology of renal cell carcinoma. *J Hypertens*. 2005 Nov;23(11):1997-2004.
 - **Linehan W.M . Lerman, M.I., and Zbar ,B.**(1995) Identification of the VHL gene . *J.AM. Med.Assoc.* 273,564-570.
 - **Linehan WM, Walther MM, Zbar B** The genetic basis of cancer of the kidney. *J Urol* 2003;170:2163-72.

- **Linehan WM, Yang JC, Bates SE** Cancer of the kidney DeVita SE Hellman S Rosenberg SA eds. . Cancer: principles and practice of oncology 7th ed. 2004 Lippincott Williams & Wilkins Philadelphia
- **Lipworth L, Tarone R. E. and McLaughli J. K.** The Epidemiology of Renal Cell Carcinoma: n J Urol 2006; 176: 2353–2358. *The Journal of Urology, Volume 177, Issue 5, May 2007, Pages 1953-1954.*
- **LjungbergB, Hanbury DC ,Kuczyk MA et al.** Guidelines on renal cell carcinoma. EAU guidelines. Pp 1-26, 2006.
- **Longuemaux S, Rodrigues-Lima F, Dupret JM.** Renal cell carcinoma and environmental factors. Prog Urol. 2003 Nov;13(5 Suppl 2):1194-6.
- **Lopez B, Scarpelli M., Montironi R., et al** WHO classification of the renal tumors of the adults, *Eur Urol* **49** (2006), pp. 798–805
- **Lorenzato A, Olivero M, Patanè, S,** Novel Somatic Mutations of the *MET* Oncogene in Human Carcinoma Metastases Activating Cell Motility and Invasion¹*Cancer Research* 62, 7025-7030, December 1, 2002].
- **Lubnesky IA, Gennera, J R., Bertheau, P., et al .** Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in VHL disease patients. AM. J. Pathol. 149;2089-2094.1996.
- **Lugli, A, Zlobec, I, Baker, K,** (2007). Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status. *J. Clin. Pathol.* 60: 534-539

- **Maina EN, Morris MR, Zatyka M**, Identification of novel VHL target genes and relationship to hypoxic response pathways. *Oncogene*. 2005 Jun 30;24(28):4549-58
- **María V., Marina T., Carina E. et al** *Journal of Histochemistry and Cytochemistry*, Vol. 51, 781-788, June 2003, Patterns of MUC1 Tissue Expression Defined by an Anti-MUC1 Cytoplasmic Tail Monoclonal Antibody in Breast Cancer
- **Marija Velickovic, Brett Delahunt, Stephan Störkel** *Cancer Research* 61, 4815-4819, June 15, 2001
- **Marston W, , Vasselli J , Srinivasan^R et al 2004** Genetic Basis of Cancer of the Kidney
- **Martignoni G,. Brunelli M , Gobbo S, et al.**, Role of molecular markers in diagnosis and prognosis of renal cell carcinoma, *Anal Quant Cytol Histol* **29** (), pp. 41–49. 2007
- **Masher E and Kaelin WG**: VHL disease 1997 *Medicine*, 76; 381-391.
- **Matsuyama H and Hirata H et al**, Smoking may cause genetic alterations at 5q22.2 approximately q23.1 in clear-cell renal cell carcinoma *Cancer Genet Cytogenet*. 2005 Nov;163(1):7-11.
- **Maynard MA and Ohh M**: VHL tumor suppressor protein and HIF in kidney cancer *Am J Nephrol* 2004 24: 1-13.
- **McLaughlin JK and Lipworth L**. Epidemiologic aspects of renal cell cancer. *Semin Oncol* 2000; **27**: 115–123.
- **Michael A, Politi E, Havranek E** Prognostic significance of erythropoietin expression in human renal cell carcinoma: *Urologic Oncology: Seminars and Original Investigations*, Volume 26, Issue 1, January-February 2008, Page 106.

- **Minardi D., Lucarini G., Mazzucchelli R et al.;** Prognostic role of Furhman grade and VEGF in pt1a clear cell carcinoma in partial nephrectomy specimens. *J Urolo.*2005;174:1208-12)
- **Mise K, Tashiro S, Yogita S et al .**Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. *Clinical Cancer Research*, Vol 4, Issue 6 1475-1482, 1998.
- **Miyata Y, Iwata T, Maruta M** Expression of Matrix Metalloproteinase-10 in Renal Cell Carcinoma and Its Prognostic Role. *European Urology, Volume 52, Issue 3, September 2007, Pages 791-797.*
- **Moch H, Gasser T, Amin MB et al.** Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell caecinoma. *Cancer*, 89:604-614, 2000
- **Mohseni HF ,. Perlmutter AE, Wilson S,.**Renal Cell Carcinoma and End Stage Renal Disease. *The Journal of Urology, Volume 175, Issue 6, June 2006, Pages 2018-2021.*
- **Mokhtar N, Gouda I and Adel I.** cancer pathology registry2003-2004-. *Pathol Dept. NCI* p 39, 2007.
- **Montorsi F.** Kidney carcer:Highlights from 2006. *European urology suppl.* Vol 6, 745-753.2007.
- **Moore LE, Wilson RT, Campleman S L.** Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. *Cancer Invest.* 2005;23(3):240-55.
- **Morris MR , Maina¹ E, Morgan² N V,** Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma *Journal of Clinical Pathology* 2004;57:706-711

- **Morris MR, Gentle D, Abdulrahman** Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. *Cancer Res.* 2005 Jun 1;65(11):4598-606.
- **Morrissey C, Martinz A, Zatyka M et al** : Epigenetic Inactivation of the RASSF1A 3p21 TSG in both CC-RCC and PRCC. *Cancer Res* 61: 7277-7281 2001.
- **Motzer RJ, Bander NH, Nanus DM.** Renal-cell carcinoma. *N Engl J Med* 1996;335:865-875
- **Murad T, Komaiko W, Oyasu R et al** : Multilocular Cystic RCC. *Am J Clin Pathol* 95: 633-637
- **Murai M and Oya M.** Renal cell carcinoma: etiology, incidence and epidemiology. *Curr Opin Urol.* 2004 Jul;14(4):229-33.
- **Nagashima Y, Miyagi Y, Udagawa K, et al** Von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization. *J Pathol* 1996;180:271-
- **Nakae S, Nakamura T, Ikagawa R et al,** Evalution of arrgyrophilic nucleolar organizer regions and PCNa in colorectal carcinoma, *J of Sur Patholo*, 69, pp 28- 35, 1998
- **Nakashima T, Nakashima T, Masuda et al.** .p53 and bcl-2 expression and argyrophilic nucleolar organizer regions in patients with malignant maxillary sinus tumours. *The Journal of Laryngology & Otology* (1997), 111:38-42
- **Nickerson ML, Warren MB, Toro JR, et al** Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. *Cancer Cell* 2002;2:157-64.
- **Nogueira M and. Kim H L.**Molecular markers for predicting prognosis of renal cell carcinoma. *Urologic Oncology: Seminars*

and Original Investigations, Volume 26, Issue 2, March-April 2008, Pages 113-124.

- **Novara G, Martignoni G and Artibani. W** Grading Systems in Renal Cell Carcinoma. *The Journal of Urology, Volume 177, Issue 2, February 2007, Pages 430-436.*
- **Novara G., Galiano A., Brunelli M.** LOSS OF CHROMOSOME 9P IN CLEAR CELL RENAL CELL CARCINOMA WITH DIFFERENT SIGN SCORE *European Urology Supplements, Volume 6, Issue 2, March 2007, Page 31*
- **Novick AC, Campbell SC:** Renal tumors in Campbell's Urology VOL 4 8th edition, Walsh PC , Retik AB, Darracott Vaughan Jr E et al . Philadelphia 2002:2672-2719.
- **O'Connell JT, Shao ZH, Drori E et al.,** Altered mucin expression in mucinous(colloid) breast carcinoma Hum Pathol, 29,pp 1517-1523, 1998.
- **Ohh M, Yauch RL, Lonergan KM, et al** The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
- **Ohh.M and Kaelin WG .** The von Hippel-lindau TSG: new persectives.Mol.Mod.Today,5;pp:257-263,1999
- **Okuda H, Saitoh K, Hirai S, et al** The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001;276:43611-7
- **Onder AM, Teomete U, Argani P, Pediatr Nephrol.** PRCC-TFE3 Renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma. 2006 Jun 29

- **Ornstien DK, Lubensky IA, Venzon D 2000:** Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary PRCC. *J Urol* 163:431-433.
- **Ozer EK, Yorukoglu O, Sagol U et al.** Prognostic significance of nuclear morphometry in renal cell carcinoma. *BJU international*, 90pp:20-25, 2002
- **Padovani, J. A. Jr.; Monteiro, R.; Zan, T** Morphometric Analysis of Nucleus and Nucleolar Organizer Regions (NORs) in Tongue Squamous Cell Carcinoma (SCC) *Int. J. Morphol.*, 25(3):493-499, 2007.
- **Paner GP, Srigley JR, Radhakrishnan A** .Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. *Am J Surg Pathol*. 2006 Jan;30(1):13-9.
- **Pantuck A J** Editorial Comment on: Collecting Duct Renal Cell Carcinoma: A Matched Analysis of 41 Cases. *European Urology*, Volume 52, Issue 4, October 2007, Pages 1145-1146.
- **Pantuck AJ, Zeng G, Arie S et al** : Pathobiology, prognosis and targeted therapy for renal cell carcinoma, 2003, 9:4641-4652).
- **Paradis V, Ferlocot S, Ghannam E et al.** CD44 is an independent prognostic factor in renal cell carcinoma. *J Urol*, 161, pp: 1984-7, 1999
- **Parker AS, Cerhan JR, Lynch CP et al.** Gender, alcohol consumption, and renal cell carcinoma. *Am J Epidemiol* 2003; **155**: 455–462
- **Parry S, Silverman HS, McDermott K** Identification of MUC1 proteolytic cleavage sites in vivo. **1:** *Biochem Biophys Res Commun*. 2001 May 11;283(3):715-20.

- **Patard J ,Kim H ,Lam J et al** Use of the California university integrated stagingsystem to predict survival in renal cell carcinoma. J Clin Oncol 22, p3316-3322, 2004.
- **Patard J, Leray E ,Rioux N et al.** Prognostic value of histological subtypes in renal cell carcinoma. J Clin Oncol.p2763-2771, 2005.
- **Patard JJ, Dorey FJ, Cindolo L.** Symptoms as well as tumor size provide prognostic information on renal tumors. J Urol 172, pp 2167-71, 2004
- **Paul R, Necknig U, Busch R et al:** Cadherin-6 a new prognostic marker for renal cell carcinoma. J Urol, 171.p97-101, 2004.
- **Paulsen F.and M. Berry,** Mucins and TFF peptides of the tear film and lacrimal appratus, *Prog Histochem Cytochem* **41** (1) (2006), pp. 1–53
- **Paulsen FP, Deike V, Paulsen AR et al.** Prognostic value of mucin in the classification of ampullary carcinoma. Hum Pathol, 37, pp 160-167, 2006.
- **Pause A, Lee SY, Ivanov A et al.**The von Hippel-Lindau TSG is required for cell cycle exit .Proc.natl.Acad.Sci.USA.95,pp: 933-998,1998.
- **Pavlovich CP, Schmidt LS, Phillips JL et al** (2002): Renal tumours in BHD syndrome .AM. J. Surg. Pathol 26;1542-1552
- **Payromaure M, Misrai V, Thiounn N, et al.** Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer 2004;100:1406-1410.
- **Payromaure M, Thiounn n, Scotte F et al,** :Collecting duct carcinoma of kidney : aclinicopathological study of 9 cases J Urolo 2003;170;1138-1140
- **Payromaure M, Thiounn n, Scotte F et al,:** Collecting duct carcinoma of kidney : aclinicopathological study of 9 cases J Urolo 2003;170;1138-1140

- **Peratla M, Moch H, Amin M et al** : Sarcomatoid differentiation of RCC . Am J Surg Pathol: 25; 275-284
- **Pertia A, Nikoleishvili D., Tsintsadze O**, IMPORTANCE OF P27(KIP1), CYCLIN D3, AND KI67 IN CONVENTIONAL RENAL CELL CARCINOMA *European Urology Supplements, Volume 6, Issue 2, March 2007, Page 31*
- **Pérula E A, -Villalobos R R, and Cuevas J F** Value of volume weighted mean nuclear volume in grading and prognosis of renal cell carcinoma. J Clin Pathol. 1994 April; 47(4): 324–328.
- **Peter B, Kathrin S., Stuhler G**, Blood, Vol. 93 No. 12), 1999: pp. 4309-4317 .Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
- **Petrolla AA and MacLennan GT** Renal Cell Carcinoma Associated With End Stage Renal Disease. *The Journal of Urology, Volume 176, Issue 1, July 2006, Page 345.*
- **Pich A , Chiusa L, Mararia E et al.** Role of argyrophilic nucleolar organizer regions in tumor detection and prognosis. Cancer Detect Prevent, 19,pp: 282-291, 1995
- **Pich A , Margaria E, Chiusa L, et al** .AgNORs count correlates better than grading with the effect of chemotherapy in serous ovarian cancer
- **Pischon T, Lahmann PH, Boeing H**, Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006 Feb 1;118(3):728-38
- **Polascik TJ, Cairns P, Epstein JI et al**: Distal nephron renal tumors ; microsatellite allotype. Cancer Res 56:1892-1895 ,1996.

- **Prasad SR , Humphrey PA , Jay R** Common and Uncommon Histologic Subtypes of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation¹ RadioGraphics 2006;26:1795-1806
- **Rabassa M E, María V C, Pereyra A,¹ et al** .MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis October 25. doi: 10.1186/1471-2407-6-253. 2006
- **Rahn JJ , Shen RO , Brian K.** et al: MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J. Biol.Chem 279; 29386-29390,2004.
- **Rahn JJ, Dabbagh L, Pasdar M** et al, .The importance of MUC-1 cellular localization n patients with breast carcinoma. Cancer , 91, pp 1973-1982, 2001
- **Raina D, Kharbanda S and KuferD** : The MUC1 oncoprotein activates the anti-apoptotic PI3K/Akt and Bcl-xl pathway in Rat 3Y1 fibroblasts. J. Biol. Chem. 279;20607-20612 2004
- **Rais-Bahrami S,. Drabick J J,. De Marzo A M.** Xp11 Translocation Renal Cell Carcinoma: Delayed but Massive and Lethal Metastases of a Chemotherapy-Associated Secondary Malignancy. *Urology, Volume 70, Issue 1, July 2007, Pages 178.e3-178.e6*
- **Rakha EA, Boyce RW, Abd El-Rehim D et al.** Expression of mucins and their prognostic significance in breast carcinoma.Mod Patholo, 18 pp 1295-1304, 2005.
- **Rakozy c, Schmahl GE, Bogner S.** Low grade tubular mucinous renal neoplasm: morphologic , immunohistochemical and genetic features. Mod .Pathol15(11) 1162-1171, 2002.
- **Ranshaw AA and Corless CL.**Papillary renal cell carcinoma. Am.J. Surg.Pathol, 19:842:849,1995.

- **Rashidkhani B, Akesson A, Lindblad P** Alcohol consumption and risk of renal cell carcinoma: a prospective study of Swedish women. *Int J Cancer*. 2005 Dec 10;117(5):848-53.
- **Raval RR, Lau KW, Tran MG.** Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. *Mol Cell Biol*. 2005 Jul;25(13):5675-86.
- **Ren Jian , Rain D, Chen W et al,** MUC-1 oncoprotein functions in activation of fibroblast growth factor signaling *Mol Cancer Reserch* 4, pp 873-883, 2006.
- **Rioux-Leclecq N, Epstein JI, Bansard et al.** Clinical significance of cell proliferation , microvessel density and CD 44 adhesion molecules expression in renal cell carcinoma . *HUM Pathol*, 11 pp, 1209-15, 2001 .
- **Rioux-Leclercq N, Fergelot P, Zerrouki S** Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. *Human Pathology, Volume 38, Issue 10, October 2007, Pages 1489-1495*
- **Robert L. Grubb III, Michael E. Franks, Jorge Toro** Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. *The Journal of Urology, Volume 177, Issue 6, June 2007, Pages 2074-2080*
- **Robson C.J., Churchill B.M. and. Anderson W,** The results of radical nephrectomy for renal cell carcinoma, *J Urol* **101** (1969), pp. 297–301.
- **Rodrigues OR , Antonangelo L, Yagi N et al,** Prognostic Significance of Argrophilic Nucleolar Organizer Region (AgNOR) in Resected Non-small Cell Lung Cancer (NSCLC) *Japanese Journal of Clinical Oncology* Pages 298-305, 2003

- Roland CL, Harken AH, Sarr MG et al . ICAM expression determines malignant potential of cancer. Surgery , 141, pp 705-707, 2007.
- **Rosia J.**Urinary tract. In Rosia and Ackerman's surgical pathology. 9th ed. Mosby. Pp: 1136-1316, 2004
- **Roupret M, Peyromaure M, Hupertan V.** Bellini renal cell carcinoma. Diagnosis and treatment Prog Urol. 2004 Sep;14(4):564-7.
- **Ruschoff J, Plate K, Thomas C et al.** NORs basic concept and practical application in tumor pathology . Pathol Res Pract 185, pp 878-885, 1989.
- **Salla C, Chatzipantelis P, Konstantinou P.** Endoscopic ultrasound –guided fine-needle aspiration cytology in the diagnosis of papillary mucinous neoplasm of the pancreas.J Pancreas, 8, pp 715-724, 2007
- **Sanders M E. *, Mick R[†]., Tomaszewski J E** Unique Patterns of Allelic Imbalance Distinguish Type 1 from Type 2 Sporadic Papillary Renal Cell Carcinoma American Journal of Pathology. 2002;161:997-1005
- **Satoh S, Hinoda Y, Hayashi T,** Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Res 2004;10(Suppl):6290s-5s.. Int J Cancer. 2005 Nov 15;88(4):507-18.
- **Schag K, Susanne M. Schmidt¹, Martin R. Müller¹.** Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes. Clinical Cancer Research Vol. 10, 3658-3666, June 1, 2004

- **Schmidt L., Duh F-M., Chen F., et al .** Germ line and somatic mutations in the tyrosine kinase domain of the *MET* proto-oncogene in papillary renal carcinomas. *Nat. Genet.*, 16: 68-73, 1997.
- **Schoenfeld A, Davidowitz E, Burk R** Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. *Int J Cancer* 2001;91:457-67
- **Schoenfeld A., Davidowitz, E.J., and Burk. R.** D1998: A second major native VHL gene product, functions as a tumour suppressor gene .*Proc. Natl. Acad. Sci.USA* 95;8817-8822.
- **Schoenfeld AR, Parris T, Eisenberger A, et al.** The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. *Oncogene* 2000;19:5851–7
- **Schouten LJ, van Dijk BA, Oosterwijk E.** Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. *J Hypertens.* 2005 Nov;23(11):1997-2004. 435-6.
- **Schraml P., Hergovitz A., Hatz Fet al.** Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression. *Am. J. Pathol.*, September 1, 2003; 163(3): 1013 - 1020.
- **Schuetz AN, Goen QY, Amin MB, et al** Molecular classification of renal tumors by gene expression profiling. *J Mol Diagn.* 2005 May;7(2):206-18
- **Scrami P, Struckman K, Hatz K et al,** VHL mutations and their correlation with tumor cell proliferation, microvessel density, and

patient prognosis in clear cell RCC,2002, J Pathology 196,186-193,3.

- **Seligson DB, Pantuck AJ, Liu X .** Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004 Apr 15;10(8):2659-69.
- **Shen RQ ,. Mah B K et al:** MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J. Biol.Chem 279; 29386-29390,2004.
- **Shi BB, Zhang XH, Wang HJ, Li HZ.** Expression of HGF and its receptor c-Met in renal cell carcinoma Zhonghua Zhong Liu Za Zhi. 2004 Jun;26(6):356-8.
- **Shimizu K , Izumi R, Ii t, et al .** Prognostic significance of nucleolar organizer regions in hepatocellular carcinoma Hepatology, Volume 21, Issue 2, February 1995, Pages 393-397.
- **Shvarts O, Lam J , Kim H et al,** Eastern cooperative oncology group performance status predicts survival in renal cell carcinoma. J Urol 172p867-870, 2004.
- **Sirri V, Roussel P, Trerè D,** et al . Amount variability of total and individual Ag-NOR proteins in cells stimulated to proliferate. *J Histochem Cytochem* 2000 ;43:887-93
- **Skolarus T A,. Serrano M F,. Berger D A.** The Distribution of Histological Subtypes of Renal Tumors by Decade of Life Using the 2004 WHO Classification *The Journal of Urology*, Volume 179, Issue 2, February 2008, Pages 439-444
- **Smith K, Gunaratnam L, Morley M** Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-

driven VHL-/- renal cancer. Cancer Res. 2005 Jun 15;65(12):5221-30.

- **Srigley JR and Moch H** Collecting duct carcinoma of the kidney
In WHO classification of tumors, pathology and genetics. Tumors of the urinary system. P10-43, 2004.
- **Srigley JR, Hutter RV, Gelb AB et al**, current prognostic factors – renal cell carcinoma. Workgroup no. 4. cancer, 80: 80:994-996, 1997.
- **Srigley JR, Kapusta L, Reuter V et al**. phenotypic, molecular and ultrastructure studies of a novel low- grade renal neoplasm related to the loop of Henle. Mod. Path. 15: 182, 2002.
- **Srigley JR**. Mucinous tubular and spindle cell carcinoma. In WHO classification of tumors, pathology and genetics. Tumors of the urinary system. P10-43, 2004.
- **Srigley JR..and Eble JN** Collecting duct carcinoma of the kidney. Semin Diag Pathol, 15:54-67, 1998.
- **Steven S and Othon L** : Molecular markers for early detection of renal carcinoma,2004.Clinicl Cancer Research 10,629S-6301S
- **Stolle C, Glenn G, Zbar B et al**, Human Mutation 12; 417-423 (1998)
- **Strokel S, Eble JN, Adlakha K et al**. Classification of renal cell carcinoma, workgroup 1 , Cancer, 80;pp: 987-989, 1997
- **Strokel S, martignoni G and vanden Berg E**. Chromophobe renal cell carcinoma . In WHO classification of tumors, pathology and genetics. Tumors of the urinary tract and male genital organs, p10-43, 2004.
- **Sudarshan S, Pinto PA, Neckers L, et al** , Hereditary leiomyomatosis and renal cell cancer — a distinct form of

hereditary kidney cancer, Nat. Clin. Pract. Urol. **4**, pp. 104–110. (2007)

- **Sufan RI , Michael A. S. Jewett AY. Renal-Cell Carcinoma. ,** The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res. 2005 Feb 1;11(3):1190-7.
- **Sufan RI, Jewett MA and Ohh M.** The role of VHL protein in renal cell carcinoma. Am J Physiol Renal Physiol, 287, pp 1-6, 2004
- **Suh KS, Chang SH, Lee HJ et al.** Clinical outcomes and apmucins expression in cholangiocarcinoma. J of the American College of Surgeons, 195, pp782-789, 2002.
- **Sukosd F., Kuroda N., Beothe T, et al.** Deletion of Chromosome 3p14.2-p25 Involving the VHL and FHIT Genes in Conventional Renal Cell Carcinoma Cancer Res., January 15, 2003; 63(2): 455 - 457.
- **Sukosed F, Digon B, Fischer J et al 2001:** Allic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe RCC: Cancer Genet. Cytogenet 128: 161-163.
- **Sültmann H, von Heydebreck A, Huber W.** Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival. Clinical Cancer Research Vol. 11, 646-655, January 2005
- **Takeuchi T, Tanaka T, Tokuyama H et al:** Multilocular cystic renal adenocarcinoma a case report. J Surg Oncol 25: 136-140 1984.
- **Tan¹ MH⁶,. Rogers GC ,. Cooper JT.** Gene Expression Profiling of Renal Cell Carcinoma Clinical Cancer Research Vol. 10, 6315S-6321S, September 15, 2004

- **Tannapfel A, Hahn HA, Katalinic A, et al.** Prognostic value of ploidy and proliferation markers in renal cell carcinoma. *Cancer*. 1996 Jan 1;77(1):164-71.
- **Tateishi M, Kaneko S, Fukuyama Y, et al .** The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung *European Journal of Surgical Oncology*, Volume 21, Issue 4, August 1995, Pages 398-402
- **Tavani A and La Vecchia C.** epidemiology of renal cell carcinoma, *J .Nephrol*, !0 93-106, 1997.
- **Theones,W., Strokel, S., and Rampelt, H.J.:** Histopathology and classification of renal cell tumors, *Path. Res. Pract* 181, 125-145 1986.
- **Thompson R, Michael D, Gillett, et al:** Costimulatory B7-H1 in renal cell carcinoma patients ,2004,101,17174-17179).
- **Tim J.D, Stoeber K ,et al** MUCX1 and Trefoil factor 1 protien expression in RCC, , Mcm2, Geminin, and Ki67 define proleferative state and are prognostic markers in RCC, *Cilic. Cancer Research*, 11,2510-2517,2005.
- **Tjin EP, Groen RW, Vogelzang I,** Functional analysis of HGF/MET signaling and aberrant HGF-activator expression **in** diffuse large B-cell lymphoma *Blood*, January 15, 2006; 107(2): 760 - 768.
- **Tokuda N, Naito S, Matsuzaki O** Collecting Duct (Bellini Duct) Renal Cell Carcinoma: A Nationwide Survey in Japan. *The Journal of Urology*, Volume 176, Issue 1, July 2006, Pages 40-43

- **Tomlinson IP, Alam NA, Rowan AJ, et al (2002)** Germline mutations in *FH* predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 30:406–
- **Tsui KH, Shvarts RB, Smith RA et al.** Prognostic indicators for renal cell carcinoma. *J Urol* 163, pp 1090-1095, 2000
- **Utsunomiya T, Yonezawa S, Sakamoto H.** Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. *Clin Cancer Res.* 1998 Nov;4(11):2605-14.
- **Van Brussel JP and Mickisch GH:** Prognostic factors in renal cell and bladder cancer. *BJU Int* 1999 May; 83(8): 902-8;
- **Van Dijk Ba, Schouten Lj, Kiemeny La., Vegetable** and fruit consumption and risk of renal cell carcinoma: results from the Netherlands cohort study *Int J Cancer.* 2005 Nov 20;117(4):648-54.
- **Van Erp F, Van Ravenswaaij C, Bodmer D et al (2003):** Chromosome 3 translocation and the risk to develop RCC. *Genet Coun* 14:149-154
- **van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA.** Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. *BMC Cancer Kidney tumors. Patholgy outlines* 2005. 2005 Jun 2;5(1):57.
- **Van Klinken BW, Einerhand AW, Buller HA ,et al.** Strategic biochemical analysis of mucins. *analytical Biochemistry* 265, pp 103-116, 1998.

- **Velickovic M, Delahunt B, McIver B, et al.** Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. *Mod Pathol* 2002; 15: 479-485
- **Velickovic M, Delahunt B, Störkel S.** *VHL* and *FHIT* Locus Loss of Heterozygosity Is Common in All Renal Cancer Morphotypes But Differs in Pattern and Prognostic Significance¹ *Cancer Research* 61, 4815-4819, June 15, 2001.
- **Velickovic M., Delahunt B., Grebe S. K. G.** Loss of heterozygosity at 3p14.2 in clear cell carcinoma is an early event and is localized to the *FHIT* gene locus. *Cancer Res.*, 59: 1323-1326, 2001.
- **Verhoest G, Veillard D, Guillé F** Relationship between Age at Diagnosis and Clinicopathologic Features of Renal Cell Carcinoma. *European Urology, Volume 51, Issue 5, May 2007, Pages 1298-1305.*
- **Warren M.B., Torres C.A., Turner M.L, .** Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues, *Mod. Pathol.* 17, pp. 998–1011.2004.
- **Weirich K, Klein B, Wohl T et al :** VHL2C phenotype in a Germin family with concurrent VHL germline mutation P81S and L188V. *J.Clin Endocrinol Metab*,87; 5241-5246 2002.
- **Weiss R H., Borowsky Ar D, Seligson D.**p21 is a Prognostic Marker for Renal Cell Carcinoma: Implications for Novel Therapeutic Approaches. *The Journal of Urology, Volume 177, Issue 1, January 2007, Pages 63-69*

- **Welch U , Oppermann T, Morteza M et al.** Secretory phenomena in non lactating mammary gland. *Annals of Anatomy* 189, pp, 131-141, 2007.
- **Welsch MJ, Krunic A, Medenica MM.** Birt-Hogg-Dube Syndrome. *Int J Dermatol.* 2005 Aug;44(8):668-73.
- **Welsch MJ, Krunic A, Medenica MM.** *Int J Dermatol.* 2005 Aug;44(8):668-73. **Birt-Hogg-Dube Syndrome.**
- **Welsh S, Williams R, Kirkpatrick L,** Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. *Mol Cancer Ther* 2004;3:233-44.
- **Wesseling J, van der Valk S W, and Hilken JA** mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. *Mol Biol Cell.* 1996 April; 7(4): 565–577.
- **Weternan MA, Wilbrink M, Geurts van Kessel A.** Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. *Proc Natl Acad Sci U S A* 2000 ;93:15294-15298
- **WHO,** classification of tumors, pathology and genetics. Tumors of the urinary system., 2004.
- **William G and Kaelin Jr** The von Hippel-Lindau Tumor Suppressor Protein: An Update. *Methods in Enzymology, Volume 435, 2007, Pages 371-383*
- **Wolk A, Lindbland p and Adami HO.** Nutrition and renal cell carcinoma, *cancer caeses Control*, 7,5-18, 1996.
- **Wykes M., MacDonald K. P, Tran M** MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells *Journal of Leukocyte Biology.* 2002;72:692-701

- **Yang AH, Wang TY, Lui HC et al.** Comparative study of the prognostic value of nuclear grade and AgNORs in renal cell carcinoma .J Pathol 1992, 166 pp: 157-161
- **Yang X J., Sugimura J., Schafernak K T** Classification of Renal Neoplasms Based on Molecular Signatures. The Journal of Urology, Volume 175, Issue 6, June 2006, Pages 2302-2306
- **Yang' XJ , Tan MH,. Kim HL** A Molecular Classification of Papillary Renal Cell Carcinoma Cancer Research 65, 5628-5637, July 1, 2005
- **Yao M, Yoshida M, Kishida T, et al** VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
- **Yasunaga Y, Shin M, Miki T et al.** Prognostic factors of renal cell carcinoma. J of Surg Oncolo 68, pp:11-18, 1998.
- **Yaun SF, Li KZ, Wang L, et al.** Expression of MUC-1 in hepatocellular and cholangiocarcinoma tissue, Word J Gastroenterol, 14 pp 4661-4666, 2006
- **Ye Y, Vasavada S, Kuzmin I, et al** Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 1998;78:62-9.
- **Yilidiz E, Gokce G, Kilcarslan H.** Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor and microvessel density in renal cell carcinoma. BJU, 93: 1087-1093, 2004.

- **Yoshino S, Kato M and Okada K.** clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. *Anticancer Res*, 20p591-594, 2000.
- **Young AN, Amin MB, Moreno CS,** Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. *Am J Pathol* 2001, 158:1639-1651.
- **Yu JC., and Shen CY.,** Two-hit Hypothesis of Tumor Suppressor Gene and Revisions. *J. Med. Sci.* 22, 13-18 (2002).
- **Yu, L.-G., Andrews, N., Zhao, Q., (2007).** Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion. *J. Biol. Chem.* 282: 773-781
- **Zbar B, Alvord WG, Glenn G, et al (2002):** Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. *Cancer Epidemiol Biomarkers Prev* 11:393–400
- **Zbar B, Glenn G, Merino M.** Familial Renal Carcinoma: Clinical Evaluation, Clinical Subtypes and Risk of Renal Carcinoma Development. *The Journal of Urology, Volume 177, Issue 2, February 2007, Pages 461-465*
- **Zbar B, Kishida T., Chen F ,et al :** Germline mutation in the VhL gene in families from North America, Europe, and Japan. *Hum. Mutat*:8;348-357 1996.
- **Zhang HK, Zhang QM, Zhao TH et al.** Expression of mucin and E-cadherin in gastric carcinoma and their clinical significance. *World J Gastroenterol*, 15, pp 3044-3047, 2004.

- **Zhao H, Ljungberg B , Grankvist K.** .. Gene Expression Profiling Predicts Survival in Renal Cell Carcinoma, PLoS Med 2006 January; 3(1): e13
- **Zimmer M, Doucette D, Siddiqui N, Iliopoulos O.** Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004;2:89-95.